Showing results (291-300 of 311) with videos related to
Sort By:
Pageof 32
Pharmacology & Therapeutics|April 29, 2022
Clinical advances in oncolytic virotherapy for pediatric brain tumorsGelare Ghajar-Rahimi, Kyung-Don Kang, Stacie K Totsch, et al.Journal of Neuro-Oncology|February 26, 2015
Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomasAsim K Bag, Hyunki Kim, Yi Gao, et al.Cancers|February 15, 2022
Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic VirotherapyColin H Quinn, Andee M Beierle, Sara Claire Hutchins, et al.Frontiers in Surgery|October 2, 2020
The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade GliomasM R Chambers, R Timothy Bentley, David K Crossman, et al.Theranostics|January 22, 2024
[89Zr]-CD8 ImmunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical modelsCarlos A Gallegos, Yun Lu, Jennifer C Clements, et al.Human Gene Therapy. Clinical Development|March 22, 2014
Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primatesJustin C Roth, Kevin A Cassady, James J Cody, et al.Pharmaceutics|February 27, 2020
MiR-219a-5p Enriched Extracellular Vesicles Induce OPC Differentiation and EAE Improvement More Efficiently Than Liposomes and Polymeric NanoparticlesI Osorio-Querejeta, S Carregal-Romero, A Ayerdi-Izquierdo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2022
Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS CancersKyung-Don Kang, Joshua D Bernstock, Stacie K Totsch, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|February 28, 2014
A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responsesJames M Markert, Shantanu N Razdan, Hui-Chien Kuo, et al.Nature Communications|April 24, 2025
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunityUpasana Sahu, Matthew P Mullarkey, Sara A Murphy, et al.Pageof 32